Personalised treatment with Flebogamma® DIF
Flebogamma® DIF is convenient for you and your patients; it is offered in 5% and 10% concentrations‡ and a wide range of vial sizes
Flebogamma® DIF is convenient for:
- Your patients
- Patient risk factors and certain clinical conditions should be considered when selecting which concentration of IVIG to use
- Your clinical practice
- Ready-to-use liquid
- Storable at room temperature (<30°C)* for the entire 2-year shelf life1
![5% & 10% Concentration](/documents/4265257/4267887/new+concentration+image.png/f89cff7a-e136-4c0a-822e-c9146754bf24?t=1560255538286)
5% concentration
- It may be an appropriate choice for patients who have frequent adverse reactions to infusions of IVIG2
- It may be suitable also for patients who would benefit from additional fluid2
- It may be appropriate for patients with renal dysfunction due to its lower osmolality and absence of sucrose, maltose or glucose2
10% concentration
- It can be infused in a lower volume being able to meet the needs of patients at risk of volume overload, including patients with heart failure3
With Flebogamma® DIF, in its wide range of vial sizes, you can personalize dosing and provide a more convenient IG treatment1
![Flebogamma DIF 5%](/documents/4265257/4267887/flebogamma-dif-5-percent-image.png/9b2096dc-a4b8-41ca-be7f-094b186d5ce2?t=1521796353174)
![Flebogamma DIF 10%](/documents/4265257/4267887/flebogamma-dif-10-percent-image.png/7ef71cf8-03af-4e52-85bd-a30517e43fe3?t=1521796364756)
Concentration matters: consider Flebogamma® DIF 5% for your high-risk patients
![Silhouettes of patients](/documents/4265257/4267887/silhouettes-patients.png/117a9f51-cf85-413a-a05b-27a5ba4d1da2?t=1533811255452)
Flebogamma® DIF 5% may be an appropriate choice for many of your patients, including those who cannot tolerate a 10% IVIG solution
In a recent trial with Flebogamma® DIF the frequency of infusions with potentially treatment-related AEs with the 5% concentration was 2.2%4
![Patient with doctor dialogue](/documents/4265257/4267887/patient-doctor-dialogue.png/26226c5b-e03f-4ea2-a0df-530738ae331d?t=1516033466070)
Patient risk factors and certain clinical conditions should be considered when selecting which concentration of IVIG to use3
High-concentration product is among the factors that predispose patients to a higher rate of systemic adverse reactions5
![Patients walking arm in arm](/documents/4265257/4267887/patients-walking-arm-in-arm.png/6f8cc89d-3dc2-492a-ad56-be9bcd109694?t=1516033466214)
Flebogamma® DIF contains low levels of isoagglutinin antibodies, and therefore may be a suitable choice for patients at increased risk of hemolysis6,7
References:
- Flebogamma® DIF EU SmPC.
- Gürcan HM, Keskin DB, Ahmed AR. Information for healthcare providers on general features of IGIV with emphasis on differences between commercially available products. Autoimmun Rev. 2010;9(8):553-559.
- Gelfand EW. Differences between IGIV products: impact on clinical outcome. Int Immunopharmacol. 2006;6(4):592-599.
- Alsina L, Mohr A, Montañés M, et al. Surveillance study on the tolerability and safety of Flebogamma® DIF (10% and 5% intravenous immunoglobulin) in adult and pediatric patients. Pharmacol Res Perspect. 2017 Oct;5(5).
- Bonilla FA. Intravenous immunoglobulin: adverse reactions and management. J Allergy Clin Immunol. 2008;122(6):1238-1239.
- Bellac CL, Hottiger T, Jutzi MP, et al. The role of isoagglutinins in intravenous immunoglobulin-related hemolysis. Transfusion. 2015;55:S13-S22.
- Jorquera JI. Flebogamma 5% DIF development: rationale for a new option in intravenous immunoglobulin therapy. Clin Exp Immunol. 2009;157(suppl 1):17-21.